Trials / Completed
CompletedNCT00391521
AS703569 Phase I in Patients With Solid Tumours
A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AS703569 | Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle |
| DRUG | AS703569 | Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle |
| DRUG | AS703569 | Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2006-10-24
- Last updated
- 2014-01-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00391521. Inclusion in this directory is not an endorsement.